Top Markets
#1 Electroneum Electroneum +19.24%
#2 Status Status +17.72%
#3 Thena Thena +12.24%
#4 Infinity Ground Infinity Ground +9.61%
#5 Ski Mask Dog Ski Mask Dog +8.58%
#6 TG.Casino TG.Casino +6.03%
#7 Bitway Bitway +4.96%
#8 City Boy City Boy +4.93%
#9 Hex Trust USD Hex Trust USD +4.55%
#10 The Grays Currency The Grays Currency +4.30%
Coin of the day
Electroneum Electroneum
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Kedudukan dalam Saham #171
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Harga Saham
$451.59
Modal Pasaran
$114.70B
Perubahan (1 hari)
-2.36%
Perubahan (1 tahun)
-11.89%
Negara
US
Perdagangan Vertex Pharmaceuticals Incorporated (VRTX)

Kategori

Healthcare
Pendapatan untuk Vertex Pharmaceuticals Incorporated (VRTX)
Pendapatan pada Dec 2025 TTM: $4.64B
Menurut laporan kewangan terkini Vertex Pharmaceuticals Incorporated, pendapatan semasa syarikat ialah $4.64B. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $248.50M, penurunan berbanding pendapatan pada tahun 2023 yang berjumlah $4.38B. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Vertex Pharmaceuticals Incorporated dari 2000 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $4.64B 0.00%
2025 $4.64B 1,768.49%
2024 $248.50M -94.33%
2023 $4.38B 3.48%
2022 $4.23B 55.01%
2021 $2.73B -12.40%
2020 $3.12B 123.45%
2019 $1.39B 132.39%
2018 $600.24M -3,925.87%
2017 $-15.69M -76.71%
2016 $-67.37M -87.96%
2015 $-559.58M -23.85%
2014 $-734.88M -24.71%
2013 $-976.12M 7,783.99%
2012 $-12.38M -120.48%
2011 $60.45M -108.01%
2010 $-754.63M 17.51%
2009 $-642.18M 38.35%
2008 $-464.18M 8.73%
2007 $-426.91M 106.35%
2006 $-206.89M 19.32%
2005 $-173.39M 9.39%
2004 $-158.51M -54.37%
2003 $-347.35M 190.28%
2002 $-119.66M 1.50%
2001 $-117.89M 119.92%
2000 $-53.61M 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B 340.58%
DK
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B 12.65%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -53.96%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -65.23%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -68.75%
NL